The Parkinson's-Reversing Breakthrough

What is Parkinsons Disease

Get Instant Access

1. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208(7):1168-1170.

2. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm 1995; 46:399-405.

3. Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL. Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 1987; 10(6):522-526.

4. Adler CH, Stern MB, Vernon G, Hurtig HI. Amantadine in advanced Parkinson's disease: good use of an old drug. J Neurol 1997; 244(5):336-337.

5. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999; 56(11): 1383-1386.

6. Farnebo LO, Fuxe K, Goldstein M, Hamberger B, Ungerstedt U. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. Eur J Pharmacol 1971; 16(1):27-38.

7. Greenamyre JT, O'Brien CF. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 1991; 48(9):977-981.

8. Ruzicka E, Streitova H, Jech R, et al. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. J Neural Transm 2000; 107(11):1297-1306.

9. Deeter RG, Khanderia U. Recent advances in antiviral therapy. Clin Pharm 1986; 5: 961-976.

10. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Phar-macokinet 1988; 14(1):35-51.

11. Pacifici GM, Nardini M, Ferrari P, Latini R, Fieschi C, Morselli PL. Effect of amantadine on drug-induced parkinsonism: relationship between plasma levels and effect. Br J Clin Pharmacol 1976; 3(5):883-889.

12. Fahn S, Craddock G, Kumin G. Acute toxic psychosis from suicidal overdosage of amantadine. Arch Neurol 1971; 25(1):45-48.

13. Symmetrel® (amantadine) package insert. Chadds Ford, PA: Endo Pharmaceuticals, 2003.

14. Trappler B, Miyashiro AM. Bupropion-amantadine associated neurotoxicity. J Clin Psychiatry 2000; 61:61-62.

15. Wilson TW, Rajput AH. Amantadine-dyazide interaction. Can Med Assoc J 1983; 129(9):974-975.

16. Factor SA, Molho ES. Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Mov Disord 1999; 14(3):515-517.

17. Greulich W, Fenger E. Amantadine in Parkinson's disease: pro and contra. J Neural Transm 1995; 46:415-421.

18. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology 1975; 25:603-606.

19. Dallos V, Heathfield K, Stone P, Allen FA. Use of amantadine in Parkinson's disease. Results of a double-blind trial. Br Med J 1970; 4(726):24-26.

20. Mann DC, Pearce LA, Waterbury LD. Amantadine for Parkinson's disease. Neurology 1971; 21(9):958-962.

21. Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. Cochrane database Syst Rev 2003; (1):CD003468.

22. Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005; 20(5):523-539.

23. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58(1):11-17.

24. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46(6):1551-1556.

25. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998; 50(5):1323-1326.

26. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003; (2):CD003467.

27. Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75(1):141-143.

28. da Silva-Junior FP, Braga-Neto P, Sueli Monte F, et al. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord 2005; 11(7):449-452.

29. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000; 47(4 suppl 1):S122-S129; discussion S129-S130.

30. Timberlake WH, Vance MA. Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 1978; 3(2):119-128.

31. Vollum DI, Parkes JD, Doyle D. Livedo reticularis during amantadine treatment. Br Med J 1971; 2(762):627-628.

32. Sladden MJ, Nicolaou N, Johnston GA, et al. Livedo reticularis induced by amantadine. Br J Dermatol, 2003; 149(3):656-658.

33. Quinn NP. Anti-parkinsonian drugs today. Drugs 1984; 28(3):236-262.

34. Shulman LM, Minagar A, Sharma K, Weiner WJ. Amantadine-induced peripheral neuropathy. Neurology 1999; 53(8):1862-1865.

35. Evidente VG, Adler CH, Caviness JN, et al. A pilot study on the motor effects of rimantadine in Parkinson's disease. Clin Neuropharm 1999; 22(1):30-32.

36. Singer C, Papapetropoulos S, Gonzalez MA, et al. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Mov Disord 2005; 20(7):873-877.

37. Shulman LM, Minagar A, Sharma K, et al. Amantadine-induced peripheral neuropathy. Neurology 1999; 53(8):1862-1865.

38. Schwab RS, Poskanzer DC, England AC, Jr., Young RR. Amantadine in Parkinson's disease. Review of more than two years' experience. JAMA 1972; 222(7):792-795.

39. Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov Disord 1998; 13(1):34-38.

40. Hughes B, Feiz V, Flynn SB, et al. Reversible amantadine-induced corneal edema in an adolescent. Cornea 2004; 23(8):823-824.

41. Fraunfelder FT, Fraunfelder FW. Drug-Induced Side Effects and Drug Interactions, 5th ed. Boston: Butterworth and Heinemann, 2001:421-422.

42. Blanchard DL. Amantadine caused corneal edema. Cornea 1990; 9:181.

43. Ohta K, Matsushima E, Matsuura M, et al. Amantadine-induced multiple spike waves on an electroencephalogram of a schizophrenic patient. World J Biol Psychiatry 2000; 1:59-64.

44. Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology 1998; 50(5):1456-1458.

45. Simpson DM, Davis GC. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 1984; 141(6):796-797.

46. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991; 39(7):708-716.

47. Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 1982; 17(1):19-23.

48. Blye E, Lorch J, Cortell S. Extracorporeal therapy in the treatment of intoxication. Am J Kidney Dis 1984; 3(5):321-338.

49. Stromberg U, Svensson TH. Further studies on the mode of action of amantadine. Acta Pharmacol Toxicol 1971; 30(3):161-171.

50. Scatton B, Cheramy A, Besson MJ, Glowinski J. Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol 1970; 13(1):131-133.

51. Von Voigtlander PF, Moore KE. Dopamine: release from the brain in vivo by amantadine. Science 1971; 174(7):408-410.

52. Allen RM. Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology. Clin Neuropharmacol 1983; 6(suppl 1):S64-S73.

53. Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm 1995; 46:97-105.

54. Grelak RP, Clark R, Stump JM, et al. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science 1970; 169(941):203-204.

55. Maj J, Sowinska H, Baran L. The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacologia 1972; 24(2):296-307.

56. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharma-copsychiatry 1999; 32(2):47-55.

57. Stoof JC, Booij J, Drukarch B, Wolters EC. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol 1992; 213(3):439-443.

58. Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ. Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther 1992; 263(2):717-724.

59. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents—preclinical studies. Neurosci Biobehav Rev 1997; 21(4):455-468.

60. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991; 206(4):297-300.

61. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992; 42:733-738.

62. Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson's disease. Mol Neuro-biol 1996; 12(1):73-94.

63. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991; 349(6308): 414-418.

64. Rajput A, Wallukait M, Rajput AH. 18 month prospective study of amantadine (Amd) for dopa (LD) induced dyskinesias (DK) in idiopathic Parkinson's disease. Can J Neurol Sci 1997; 24:S23.

65. Snow BJ, Macdonald L, Mcauley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000; 23:82-85.

66. Luginger E, Wenning GK, Bosch S, et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000; 15(5):873-878.

67. Shoulson I, Penney J, McDermott M, et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001; 56(4):455-462.

68. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 1996; 736(1-2):202-205.

69. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995; 701(1-2):13-18.

70. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998; 13(5):798-802.

71. Ferreira JJ, Rascol O. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Opin Neurol 2000; 13(4):431-436.

72. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(11 suppl 5):S1-S88.

73. Friedman Z, Neumann E. Benzhexol-induced blindness in Parkinson's disease. Br Med J 1972; 1(800):605.

74. Duvoisin RC, Katz R. Reversal of central anticholinergic syndrome in man by physostig-mine. JAMA 1968; 206(9):1963-1965.

75. de Leon J, Canuso C, White AO, Simpson GM. A pilot effort to determine benztropine equivalents of anticholinergic medications. Hosp Comm Psychiatry 1994; 45(6):606-607.

76. Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003; (2):CD003735.

77. Schrag A, Schelosky L, Scholz U, Poewe W. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Mov Disord 1999; 14(2):252-255.

78. Weiner WJ, Lang AE. Parkinson's Disease. In: Movement Disorders, A Complete Survey. New York: Futura Publishing Co., 1989:95.

79. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23(1):73-78.

80. Hyson HC, Jog MS, Johnson A. Sublingual atropine for sialorrhea secondary to parkinsonism. Parkinsonism Related Disord 2001; 7(suppl):194.

81. Marjama-Lyons J, Koller W. Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 2000; 16(4):273-278.

82. Nastuk WL, Su P, Doubilet P. Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976; 264(5581):76-79.

83. Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 1984; 82(3):147-150.

84. Bedard MA, Lemay S, Gagnon JF, Masson H, Paquet F. Induction of a transient dysexec-utive syndrome in Parkinson's disease using a subclinical dose of scopolamine. Behav Neurol 1998; 11(4):187-195.

85. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003; 54(2):235-8.

86. Burke RE, Fahn S. Pharmacokinetics of trihexyphenidyl after short-term and long-term administration to dystonic patients. Ann Neurol 1985; 18(1):35-40.

87. Whitehouse PJ, Hedreen JC, White CL, 3rd, Price DL. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 1983; 13(3):243-248.

88. Ruberg M, Ploska A, Javoy-Agid F, Agid Y. Muscarinic binding and choline acetyltrans-ferase activity in Parkinsonian subjects with reference to dementia. Brain Res 1982; 232(1):129-139.

89. Barbeau A. The pathogenesis of Parkinson's disease: a new hypothesis. Canad Med Ass J 1962; 87:802-807.

90. Coyle JT, Snyder SH. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 1969; 166(907):899-901.

91. Olney JW, Price MT, Labruyere J, et al. Anti-parkinsonian agents are phencyclidine agonists and N-methyl- aspartate antagonists. Eur J Pharmacol 1987; 142(2):319-320.

Was this article helpful?

0 0
All About Alzheimers

All About Alzheimers

The comprehensive new ebook All About Alzheimers puts everything into perspective. Youll gain insight and awareness into the disease. Learn how to maintain the patients emotional health. Discover tactics you can use to deal with constant life changes. Find out how counselors can help, and when they should intervene. Learn safety precautions that can protect you, your family and your loved one. All About Alzheimers will truly empower you.

Get My Free Ebook

Post a comment